



/631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Jonathan M. J. Derry, William C. Fanslow III,
and William C. Dougall

Docket No.: 3198

Group Art Unit: 1631

Serial No: 09/851,673

Examiner: C. Smith

Filed: May 8, 2001

For: SCREENING ASSAYS FOR AGONISTS OR ANTAGONISTS OF CD40
SIGNALING#11
Plunkett
2/6/03SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT RECEIVED

BOX NON FEE

Commissioner for Patents
Washington, D.C. 20231

FEB 05 2003

TECH CENTER 1600/2900

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449, and a copy of each is enclosed. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Submission of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103, and Applicants specifically reserve the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. A copy of the communication is enclosed.

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

Respectfully submitted,

Patricia Anne Perkins
Registration No. 34,693CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON FEE, Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: 1/30/2003

By:

Camilla C. Edwards